The TRT Turnaround: How New Research Led the FDA to Reverse Testosterone Warnings
A Decade of Data: How the TRAVERSE Trial Reshaped the FDA's Testosterone Guidelines From Caution to Clarity: The FDA's Evolving Stance on Testosterone Warnings (2015 vs. 2025) In the realm of public opinion, even that of healthcare professionals, there has been a great deal of misconceptions involving the safety and efficacy of testosterone when used as a medication in the past several decades. This is mostly based on faulty research and clinical trials that were poorly designed and easily disproven. Medical guidance and governance of testosterone replacement therapy (TRT) has been significantly shaped by regulation from the U.S. Food and Drug Administration (FDA) which has finally taken a more educated approach and is now saying what many of us have known all along. In 2015 , the FDA issued a stringent label warning for testosterone products, largely driven by concerns about heart health and potential cardiovascular risks. This warning was concerning to many patients an...